Abstract
AptarGroup will report fourth-quarter fiscal results on February 05, 2026, Post Market; this preview compiles last quarter’s performance, the company’s internal projections for the current quarter, and the prevailing analyst consensus to frame likely revenue, margins, and adjusted EPS outcomes.
Market Forecast
For the current quarter, AptarGroup’s management-level forecast points to revenue of $0.88 billion, an estimated gross margin assumption consistent with recent trends near 37.78%, net profit dynamics implied by a net margin close to 13.31%, and adjusted EPS of $1.23, with year-over-year changes of 3.51% for revenue and a decline of 3.01% for EPS; EBIT is guided at $0.11 billion with an estimated year-over-year decline of 3.66%. The main business portfolio is expected to remain stable, with demand resilience in the Pharmacy unit and steady volumes in Beauty and Closures supporting the quarter’s mix; the most promising segment appears to be Pharmacy, supported by durable end-market demand and innovation in dispensing systems, though growth is likely modest this quarter.
Last Quarter Review
In the previous quarter, AptarGroup delivered revenue of $0.96 billion, a gross profit margin of 37.78%, GAAP net profit attributable to the parent company of $0.13 billion, a net profit margin of 13.31%, and adjusted EPS of $1.62, representing year-over-year growth of 5.70% in revenue and 8.73% in adjusted EPS. A notable highlight was an EBIT outcome of $0.15 billion, ahead of the company’s pre-quarter estimate by $3.93 million, reflecting disciplined pricing and operational efficiency. The main business mix featured Pharmacy at $0.45 billion, Beauty at $0.33 billion, and Closures at $0.19 billion, with strong Pharmacy demand and stable Beauty and Closures revenue; year-over-year growth was strongest in Pharmacy, supported by new solutions and solid replenishment cycles.
Current Quarter Outlook (with major analytical insights)
Pharmacy (Main Business)
Pharmacy remains AptarGroup’s anchor business, evidenced by last quarter’s $445.41 million revenue contribution and its sizable share of group sales. For the current quarter, the company’s forecast signals stable demand patterns in prescription and over-the-counter dispensing systems, while new launches and customer programs continue to underpin volumes. Gross margin sustainability hinges on the continued mix of higher-value dispensing components and manufacturing efficiencies, and the implied net margin near recent levels suggests limited pricing pressure. Risks revolve around timing of customer orders and potential inventory normalization as healthcare channels fine-tune stock levels after robust replenishment phases. Given the relatively defensive nature of the end markets, Pharmacy is positioned to support consolidated revenue, with its innovation pipeline keeping orders resilient even if broader industrial demand softens.
Beauty (Most Promising Business)
Beauty is set up as the most promising growth contributor in this quarter’s framework due to ongoing SKU refreshes and customer engagements in prestige and mass channels. While last quarter revenue reached $327.77 million, momentum in component upgrades and sustainable designs can lift mix and preserve margin quality. The quarter may face uneven demand across regions, but product differentiation and long-cycle customer relationships provide a buffer against abrupt volume swings. Pricing discipline and supply chain normalization should help EBIT hold near guidance ranges, even as the company navigates promotional calendars in personal care. If consumer-facing brands pull forward packaging redesigns, Beauty could outgrow the consolidated average, reinforcing its role in sequential performance stability.
Closures
Closures, with last quarter revenue of $187.95 million, continues to contribute stable cash generation, though growth expectations are more measured in the near term. The category’s performance is tied to consumer staples and household product volumes, where demand tends to be steady but less cyclical than discretionary categories. The margin profile relies on cost controls and incremental improvements in tooling and materials, and the company has demonstrated operational execution that keeps profitability in line with the broader portfolio. For this quarter, closures should maintain baseline revenue and help smooth consolidated results, even if broader macro trends introduce variability in unit volumes.
Share Price Drivers This Quarter
Near-term stock performance will be most sensitive to whether reported revenue aligns with the $0.88 billion forecast and whether adjusted EPS of $1.23 meets expectations amid the guided year-over-year decline. Margin commentary—specifically gross margin relative to last quarter’s 37.78% and net margin against the 13.31% level—will be scrutinized to gauge cost inflation, pricing, and mix durability. Any updates on project launches in Pharmacy or Beauty that influence second-half visibility could recalibrate investor expectations, while execution on operational initiatives that supported last quarter’s EBIT outperformance would support confidence in guidance.
Analyst Opinions
Bullish opinions modestly outweigh cautious views based on recent institutional commentary, with the dominant side pointing to resilient end-market demand and consistent margin delivery. Analysts highlight that management’s forecast of $0.88 billion revenue and $1.23 EPS indicates a prudent stance yet remains consistent with sustained profitability, underpinned by stable Pharmacy demand and improving Beauty mix. Well-regarded institutions emphasize the importance of disciplined pricing and cost efficiencies that helped deliver last quarter’s $147.37 million EBIT above expectations, supporting the view that the company can navigate modest EPS pressure while preserving healthy cash flows. Consensus on the majority side anticipates the reported results to be broadly in line with guidance, with upside risk if Beauty program ramps and Pharmacy orders are slightly ahead of plan, while maintaining vigilance on EBIT trends and margin resilience as indicators for the next fiscal period.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments